Omalizumab

[MAF] Omalizumab (Xolair) Injection 150 mg

1. Additional clinical criteria applies
   
   As an add-on therapy to H₁-antihistamines for treating severe chronic spontaneous urticaria (CSU) in patients aged 12 years and older, with a mean weekly Urticaria Activity Score (UAS

2. of 28 and above, despite the use of, or who are intolerant to, four-times registered dose of second generation non-sedating H₁-antihistamines.
   
   A maximum of six 300 mg doses of omalizumab should be administered for each treatment course. Re-treatment with omalizumab can be considered upon relapse for patients who achieve an adequate response during the previous treatment course. Adequate response to omalizumab is defined as a UAS7 score of six or below while on treatment.

[MAF] Omalizumab (Xolair) Prefilled Syringe 150 mg/mL

1. Additional clinical criteria applies
   
   As an add-on therapy to H₁-antihistamines for treating severe chronic spontaneous urticaria (CSU) in patients aged 12 years and older, with a mean weekly Urticaria Activity Score (UAS

2. of 28 and above, despite the use of, or who are intolerant to, four-times registered dose of second generation non-sedating H₁-antihistamines.
   
   A maximum of six 300 mg doses of omalizumab should be administered for each treatment course. Re-treatment with omalizumab can be considered upon relapse for patients who achieve an adequate response during the previous treatment course. Adequate response to omalizumab is defined as a UAS7 score of six or below while on treatment.

View legend

06/02/2026 Biologics as add-on therapy for severe asthma

The Ministry of Health’s Drug Advisory Committee has recommended:

• Benralizumab 30 mg/1 mL autoinjector pen for treating severe eosinophilic asthma; and

• Omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes for treating severe allergic asthma.

Funding status

[R] Benralizumab 30 mg/ml autoinjector pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.

[R] Benralizumab should be used in line with the additional clinical criteria for initiation and renewal listed in the Annex.

[R] Omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes are recommended for inclusion on the Standard Drug List (SDL) from 1 April 2026.

[NR] SDL subsidy and MAF assistance do not apply to any formulations or strengths of dupilumab, mepolizumab, omalizumab reference biologic (Xolair) or tezepelumab for treating severe asthma.

06/02/2026 Omalizumab biosimilar for treating inflammatory conditions

The Ministry of Health’s Drug Advisory Committee has recommended omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes for listing on the MOH Standard Drug List (SDL). The decision was based on acceptable clinical and cost effectiveness.

Funding status

[R] SDL subsidy will apply from 1 April 2026 to all registered indications of omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes in Singapore.

[NR] SDL subsidy does not apply to other brand(s), formulation(s) or strength(s) of omalizumab.

View legend

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration